CGRP Antagonists

• US 20080139537A1
• Filed: 06/08/2007
• Published: 06/12/2008
• Est. Priority Date: 06/08/2006
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG), Ford Global Technologies, LLC (Ford Motor Company)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: ARNDT, Kirsten, DOODS, Henri, MUELLER, Stephan Georg, RUDOLF, Klaus, SCHAENZLE, Gerhard, BOUYSSOU, Thierry
• Granted Patent: US 7,807,666 B2
• Time in Patent Office: Days
• US Class Current: 514/221
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method for preventing and treating visceral pain and gastrointestinal disorders such as functional bowel disorders and inflammatory bowel diseases through the use of effective amounts of a compound acting as CGRP antagonist.

Claims

1. A method for treating a gastrointestinal disorder which comprises administering, to a host suffering from a gastrointestinal disorder, a therapeutically effective amount of a compound selected from the group consisting of:

2. A method for treating a gastrointestinal disorder which comprises administering to a host suffering from a gastrointestinal disorder a therapeutically effective amount of a compound selected from the group consisting of:

3. The method of claim 2 wherein the gastrointestinal disorder is selected from the group consisting of functional bowel disorders and the inflammatory bowel diseases.

4. The method according to claim 3, wherein the gastrointestinal disorder is selected from the group consisting of gastro-esophageal reflux, dyspepsia, the irritable bowel syndrome and functional abdominal pain syndrome.

5. The method according to claim 3, wherein the inflammatory bowel disease is selected from the group consisting of Crohn'"'"'s disease, ileitis and ulcerative colitis.

6. The method according to claim 3, wherein the functional bowel disorder is the irritable bowel syndrome.